Complementary pharmacological inhibition experiments demonstrated that targeted suppression of PAK2 activity abolished Cd‐driven malignant progression in BC models (Figure S11, Supporting Information), confirming the essential role of PAK2 in the cancer‐promoting effects of Cd. This evidence concerns the gene PAK2 and breast cancer.